Abstract
Colorectal cancer is one of the major causes of cancer mortality in the elderly population (median age at diagnosis of 71 years) in Western Countries. Moreover patients with metastatic disease are often elderly with significant co- morbidities. Unfortunately, elderly patients are often untreated and under-represented in clinical trials, even if most clinical trials that have included this setting of population have shown similar survival rates and toxicities to younger patients.
Age itself should not be considered for candidacy to chemotherapy but it should be taken in consideration the great heterogeneity of co-morbidities present in the elderly population. Therefore, the best treatment strategy for elderly colorectal cancer patients has not yet been defined. Comprehensive Geriatric Assessment is recommended to evaluate the best strategy treatment and to reduce the adverse events. In fact, while fit elderly patients could receive the same therapeutic treatment as the younger counterpart, a palliative approach should be taken in consideration for frail elderly patients and for those with a short life expectancy.
Keywords: Elderly, colorectal, cancer, chemotherapy, treatment.
Anti-Cancer Agents in Medicinal Chemistry
Title:Colorectal Cancer in Elderly Patients: From Best Supportive Care to Cure
Volume: 13 Issue: 9
Author(s): Massimiliano Berretta, Fabrizio Di Benedetto, Raffaele Di Francia, Emanuele Lo Menzo, Sergio Palmeri, Umberto Tirelli and Paolo De Paoli
Affiliation:
Keywords: Elderly, colorectal, cancer, chemotherapy, treatment.
Abstract: Colorectal cancer is one of the major causes of cancer mortality in the elderly population (median age at diagnosis of 71 years) in Western Countries. Moreover patients with metastatic disease are often elderly with significant co- morbidities. Unfortunately, elderly patients are often untreated and under-represented in clinical trials, even if most clinical trials that have included this setting of population have shown similar survival rates and toxicities to younger patients.
Age itself should not be considered for candidacy to chemotherapy but it should be taken in consideration the great heterogeneity of co-morbidities present in the elderly population. Therefore, the best treatment strategy for elderly colorectal cancer patients has not yet been defined. Comprehensive Geriatric Assessment is recommended to evaluate the best strategy treatment and to reduce the adverse events. In fact, while fit elderly patients could receive the same therapeutic treatment as the younger counterpart, a palliative approach should be taken in consideration for frail elderly patients and for those with a short life expectancy.
Export Options
About this article
Cite this article as:
Berretta Massimiliano, Benedetto Di Fabrizio, Francia Di Raffaele, Menzo Lo Emanuele, Palmeri Sergio, Tirelli Umberto and Paoli De Paolo, Colorectal Cancer in Elderly Patients: From Best Supportive Care to Cure, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (9) . https://dx.doi.org/10.2174/18715206113136660350
DOI https://dx.doi.org/10.2174/18715206113136660350 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Function of miRNA in Controlling Drug Resistance of Human Cancers
Current Drug Targets Effects of Tea Polyphenols and their Polymers on MAPK Signaling Pathways in Cancer Research
Mini-Reviews in Medicinal Chemistry Pemetrexed: Potential Role in the Adjuvant Chemotherapy of Non-Small Cell Lung Cancer
Current Drug Targets Alternative Splice Variants of Survivin as Potential Targets in Cancer
Current Drug Discovery Technologies Irinotecan or Oxaliplatin: Which is the First Move for the Mate?
Current Medicinal Chemistry The Epithelial-Mesenchymal Transition and Cancer Stem Cells: Functional and Mechanistic Links
Current Pharmaceutical Design A Review on Clinical Management and Pharmacological Therapy on Hereditary Haemorrhagic Telangiectasia (HHT)
Current Vascular Pharmacology Mesenchymal Stem Cells: A New Generation of Therapeutic Agents as Vehicles in Gene Therapy
Current Gene Therapy A Review on the Expression and Metabolic Features of Orphan Human Cytochrome P450 2S1 (CYP2S1)
Current Drug Metabolism Telomerase and Survivin in Colorectal and Pancreatic Cancer – Biomarkers of Life and Death in the Balance Between Proliferation and Apoptosis
Current Cancer Therapy Reviews Guggulsterone for Chemoprevention of Cancer
Current Pharmaceutical Design Differentiated Thyroid Carcinoma and Intestinal Polyposis Syndromes
Endocrine, Metabolic & Immune Disorders - Drug Targets Oncotarget Strategies For Herpes Simplex Virus-1
Current Gene Therapy Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Current Status and Future Perspectives in the Development of Novel Irreversible Inhibitors for the Treatment of Mutant Non-small Cell Lung Cancer
Current Pharmaceutical Design Saffron-Based Crocin Prevents Early Lesions of Liver Cancer: In vivo, In vitro and Network Analyses
Recent Patents on Anti-Cancer Drug Discovery ROS-Responsive Nanomedicine: Towards Targeting the Breast Tumor Microenvironment
Current Medicinal Chemistry Possible Molecular Mechanisms by which Vitamin D Prevents Inflammatory Bowel Disease and Colitis-associated Colorectal Cancer
Current Medicinal Chemistry Mesenchymal stem cell therapy for inflammatory bowel diseases: promise and challenge
Current Stem Cell Research & Therapy A Hemagglutinin from Northeast Red Beans with Immunomodulatory Activity and Anti-proliferative and Apoptosis-inducing Activities Toward Tumor Cells
Protein & Peptide Letters Cyclooxygenase as a Target for Colorectal Cancer Chemoprevention
Current Drug Targets